Skip to content
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
featured-image

Press Release

RapidAI Receives FDA Clearance of AI Module for Detection of Hemispheric Subdural Hematomas

Further enhancing comprehensive trauma care solution SAN MATEO, Calif., – November 9, 2023 – RapidAI, the global leader in developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, trauma, cardiac and vascular conditions, today announced it has received FDA clearance for Rapid SDH, its AI-powered module for the detection and notification of suspected hemispheric acute and chronic subdural hematoma.
featured-image

Press Release

Texas County Memorial Hospital Goes Live with RapidAI to Enhance Neurovascular Decision Making and Rural Stroke Care

Partnership will enhance the quality of stroke care available to rural communities in southern Missouri Partnership will enhance the quality of stroke care available to rural communities in southern Missouri
featured-image

Press Release

RapidAI Announces $75 Million Growth Investment Led by Vista Credit Partners

Funding intended to fuel continued innovation of RapidAI’s advanced clinical decision and workflow support technology; further establish a leadership position in clinical AI solutions
featured-image

Press Release

RapidAI Wins MedTech Breakthrough Award for Best New Imaging Solution

The recognition comes on the heels of major achievements in the past year, including 5 FDA clearances, the Frost & Sullivan Global Technology Innovation Leadership Award, and nearly 10 million patient scans The recognition comes on the heels of major achievements in the past year, including 5 FDA clearances, the Frost & Sullivan Global Technology Innovation Leadership Award, and nearly 10 million patient scans
featured-image

Press Release

RapidAI Receives First and Only FDA 510(k) Clearance of Non-Contrast CT Imaging Product to Accelerate Acute Stroke Triage

Part of RapidAI’s industry-leading stroke solution, Rapid NCCT Stroke supports faster treatment and transfer decisions while driving greater equity of care San Mateo, Calif. — April 18, 2023 — RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for Rapid NCCT Stroke – a major addition to the RapidAI suite of non-contrast based solutions for stroke and trauma care, and the first and only FDA cleared medical device to detect suspected intracranial hemorrhage (ICH) and large vessel occlusion (LVO) from value-based CT imaging.
featured-image

Press Release

The Brain Aneurysm Foundation (BAF) Welcomes RapidAI’s Carolina Maier, PhD to Board of Directors

Maier brings decades of expertise in aneurysm research to the esteemed Board of Directors Boston, MA and San Mateo, CA.— March 23, 2023 – The Brain Aneurysm Foundation (BAF), the leading global research and advocacy organization committed to improving treatment and care for brain aneurysms, today announced the addition of Carolina Maier, PhD, Vice President of Clinical Affairs at RapidAI, the global leader in using AI to combat vascular and neurovascular conditions, to the Board of Directors.
featured-image

Press Release

RapidAI Enhances Pulmonary Embolism Care Solution with FDA 510(k) Clearance for Rapid RV/LV

Integrated with the Rapid PE solution, Rapid RV/LV further accelerates time to triage and diagnose pulmonary embolism patients with right heart strain SAN MATEO, CALIF. – February 22, 2023 – RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for Rapid RV/LV, the newest addition to the Rapid PE solution. The tool empowers physicians to quickly assess the ratio between the right ventricle (RV) and the left ventricle (LV), a key indicator of pulmonary embolism (PE) severity. Automating this process will enable care teams to more quickly prioritize patients and accelerate decision making.
featured-image

Press Release

Rapid ICH Receives New FDA Clearance with Highest Sensitivity and Specificity on the Market

RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA 510(k) clearance for the latest release of Rapid ICH. New version of ICH reduces notification fatigue with a near perfect false positive rejection rate; and allows medical teams to make faster decisions for improved hemorrhage management
featured-image

Press Release

RapidAI Applauded by Frost & Sullivan for Delivering Quality Care Quickly and Securely With Its RapidAI Platform

RapidAI Applauded by Frost & Sullivan for Delivering Quality Care Quickly and Securely With Its RapidAI Platform SAN ANTONIO, TX. – September 12, 2022 – Frost & Sullivan recently analyzed the artificial intelligence (AI) algorithms for the stroke market, and, based on its assessment results, recognizes RapidAI with the 2022 Global Technology Innovation Leadership Award. The company is a leading provider of advanced imaging for stroke. It is a pioneer in AI-based treatment for vascular and neurovascular conditions and offers innovative solutions for more stroke diagnosis modalities than any other company in the space. RapidAI’s world-class subject matter experts developed advanced cerebrovascular imaging and workflow solutions over the last decade. The company refined its holistic approach to care for life-threatening neurovascular and vascular conditions, continuously building its comprehensive software platform to bridge the care gaps.
1 2 3 4